Last reviewed · How we verify
Extraneal
At a glance
| Generic name | Extraneal |
|---|---|
| Sponsor | Vantive Health LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- Effectiveness of Two Icodextrin Exchanges on Fluid Status and Blood Pressure Control Compared to a Single Icodextrin Exchange (NA)
- Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients (PHASE3)
- IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients (PHASE4)
- IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients (PHASE3)
- Heart Failure and Peritoneal Ultrafiltration (PHASE2)
- Assessment of Bioimpedance and Vitamin D and LV Mass in PD Patients (FLUID Study) (PHASE2)
- PMCF Study for ADEPT® in LaparoscopicGynecologic Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extraneal CI brief — competitive landscape report
- Extraneal updates RSS · CI watch RSS
- Vantive Health LLC portfolio CI